Abbott Laboratories stock has fallen 32.0% over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and traditional valuation multiples currently point to the shares trading at a discount to underlying fundamentals.
- The 32.0% one year decline sets expectations low, which can create room for share prices to close the gap if the valuation signals prove accurate.
- Progress in areas like blood based Alzheimerās testing and diabetes sensing technology can support long term cash flow expectations. At the same time, ongoing legal and regulatory issues may weigh on how much of that potential investors are willing to price in.
- Abbott Laboratories screens as undervalued in 6 of 6 valuation checks, so the broader toolkit leans toward the stock being cheap rather than fully priced.
The issue now is whether that apparent discount to intrinsic value and the multiples view offers a margin of safety that compensates for the business and headline risks around Abbott Laboratories.
Find out why Abbott Laboratories' -32.0% return over the last year is lagging behind its peers.
Is Abbott Laboratories a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model values Abbott Laboratories by projecting future free cash flows and discounting them back to today. On this set of assumptions, Abbottās latest twelve month free cash flow is about $7.1b, with the model treating that as a growing stream rather than a one off spike. That cash generation, run through a 2 Stage Free Cash Flow to Equity framework, leads to an estimated intrinsic value of about $140.95 per share.
With a current share price near $89, the DCF implies roughly a 35.6% discount to what Abbott Laboratoriesā cash flows support. The marketās caution after issues such as the infant formula probe, which is now moving toward a civil settlement, helps explain why the price sits below this intrinsic value estimate.
On this cash flow view, Abbott Laboratories stock appears undervalued relative to the DCF based estimate of intrinsic value.
Our Discounted Cash Flow (DCF) analysis suggests Abbott Laboratories is undervalued by 35.6%. Track this in your watchlist or portfolio, or discover 43 more high quality undervalued stocks.
Is Abbott Laboratories a Bargain on Earnings?
The P/E ratio suits Abbott Laboratories because earnings are a key focus for many investors in large, diversified healthcare companies. Abbott trades on a P/E of about 25.3x, which is slightly below the Medical Equipment industry average of roughly 25.6x and below the peer group average near 30.5x.
The fair P/E ratio implied by Abbottās profile is around 30.2x, which sits meaningfully higher than the current 25.3x level. That gap suggests the market is pricing Abbott Laboratories at a discount to what would typically be expected given its size, margins and risk mix. Put differently, the stock is not only under the tailored fair P/E mark but also sits under the broader peer average, even as the company continues to feature in areas like diagnostics and diabetes care.
On this earnings multiple view, Abbott Laboratories stock appears undervalued relative to where its P/E might reasonably sit.
See what the numbers say about this price ā find out in our valuation breakdown.
The Abbott Laboratories Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Abbott Laboratories pick up where the valuation work leaves off by spelling out which combinations of growth, margins and earnings would need to play out for the stock to be worth materially more or less than todayās price. Each one connects its number to a clear view on how Abbott Laboratories' growth, profitability and risks might evolve, giving you a reference point you can revisit as fresh information comes through.
Here is a chance to add your voice to the Abbott Laboratories story by setting out a number driven view on whether developments like blood based Alzheimerās testing and dual glucose ketone sensors ultimately reshape what todayās price implies.
Share a Narrative that lays out your case on Abbott Laboratories' valuation, growth and risk trade off, and track how it holds up as new data, approvals and legal outcomes come through.
Do you think there's more to the story for Abbott Laboratories? Head over to our Community to see what others are saying!
The Bottom Line
For Abbott Laboratories, both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple view currently point to the stock looking undervalued, with the broader valuation toolkit reinforcing that message rather than contradicting it. The crux is whether the gap between price and intrinsic value closes as the market reassesses cash flow durability and earnings quality in areas like diagnostics and diabetes care, or whether legal and regulatory overhangs keep a lid on the multiple. The key debate from here is whether that discount reflects mispricing or is fair compensation for those ongoing risks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com